Heart News and Research

RSS

MedImmune, U-M to work toward new biologic options for cancer and other diseases

Leaders from the University of Michigan Medical School and MedImmune, the global biologics arm of AstraZeneca, have signed a new agreement to work together on a broad range of projects.

22 Nov 2011

Infarct size associated with time of day onset of ischemia

The size of a heart attack and subsequent left-ventricular function are significantly different based on the time of day onset of ischemia, according to a first of its kind study in humans, published online Nov. 17 in Circulation Research.

22 Nov 2011

CUMC presents 2011 Naomi Berrie Award to UMDNJ researcher

Columbia University Medical Center (CUMC) presented the 2011 Naomi Berrie Award to Barry E. Levin, MD, a University of Medicine & Dentistry of New Jersey researcher whose work focuses on the mechanisms by which specialized metabolic-sensing neurons regulate glucose and energy homeostasis. Junior investigator Kazuhisa Watanabe, at Columbia University Medical Center, received a Berrie Fellow award.

22 Nov 2011

CRF to sponsor Women's Heart Health Summit

The Cardiovascular Research Foundation (CRF) will sponsor the Women's Heart Health Summit: "In Pursuit of Excellence: Improving Cardiovascular Outcomes in Women." The goal of the meeting is to examine current prevention, treatment, and key research issues to collectively identify opportunities and recommendations that will lead to improved cardiovascular outcomes in women.

22 Nov 2011

CardioComm demonstrates HeartCheck ECG monitor at Medica 2011

At the world's largest medical trade fair, Medica 2011 held in Düsseldorf last week, CardioComm Solutions, Inc. demonstrated their newly developed remote patient ECG monitoring service, called HeartCheck Smart Monitoring

22 Nov 2011

South Asian patients with CAD more likely to need repeat PCI procedures

South Asian patients with coronary artery disease were almost three times as likely to be readmitted to hospital for further interventional treatment to arterial plaque than their White European counterparts, according to research in the December issue of IJCP, the International Journal of Clinical Practice. They were also more likely to present as an emergency and require urgent treatment.

22 Nov 2011

FDA allows marketing of Aptus EndoStapling System to treat AAA

The U.S. Food and Drug Administration today allowed marketing of the first system that can repair a failed or problematic aortic endograft, a fabric tube used to repair a dangerously large aortic aneurysm, a bulge in the large blood vessel that carries blood away from the heart.

22 Nov 2011

Hypertension on the rise in Canada

Hypertension in Canada is increasing, and it is projected that more than one-quarter of Canadian adults will be diagnosed with hypertension by 2012/13, according to a study in CMAJ.

22 Nov 2011

Scientists discover second faulty gene linked to ALS

Following a major Northwestern Medicine breakthrough that identified a common converging point for all forms of amyotrophic lateral sclerosis (ALS and Lou Gehrig's disease), a new finding from the same scientists further broadens the understanding of why cells in the brain and spinal cord degenerate in the fatal disease.

21 Nov 2011

FDA clears Aptus EndoStapling System to treat AAA

Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Aptus EndoStapling System, which will now be known as the HeliFX™ Aortic Securement System.

21 Nov 2011

Breast cancer drug Avastin loses FDA support

According to a Food and Drug Administration (FDA) announcement last Friday, the cancer drug Avastin should not be used to treat breast cancer that has spread to other organs because it doesn't help patients enough to justify its risky side effects.

21 Nov 2011

Health policies, entitlements grab headlines in GOP campaign coverage

Newt Gingrich's health policies are getting a thorough review as his standings in the polls improve. In the background, Mitt Romney blames President Barack Obama for the super committee's difficulties.

21 Nov 2011

Viewpoints: Finding savings in Medicare; The Avastin saga; Changes in health care business

There is no way to wrestle down the deficit without reining in Medicare costs. Ensuring that the program provides quality health care coverage to millions of older and disabled Americans is essential. These goals are not incompatible, but they require a judicious approach to policy making that is depressingly absent in Washington.

21 Nov 2011

State roundup: Provider groups merging - or not

A selection of health policy stories from California, Illinois, Georgia, Connecticut, Minnesota, Michigan and Massachusetts.

21 Nov 2011

The untold stories of children of sperm donors

From Jennifer Lahl and The Center for Bioethics and Culture, producers of the award-winning Eggsploitation (2010), Anonymous Father's Day presents the untold stories of children of sperm donors.

21 Nov 2011

ChanRx to evaluate AFIB drug, vanoxerine with closed Series A funding

ChanRx is developing a superior drug for treatment of atrial fibrillation (AFIB), and has closed its Series A funding with investments from Sante Ventures and company founder, Dr. Arthur "Buzz" Brown. The company, a spin out of Cleveland-based ChanTest, will use the funding to further evaluate the safety and efficacy of its proprietary AFIB drug, vanoxerine.

21 Nov 2011

UTHealth and Memorial Hermann HVI first in Houston to implant FDA approved artificial heart valve

Cardiologists and cardiovascular surgeons at The University of Texas Health Science Center at Houston and Memorial Hermann Heart & Vascular Institute are the first in Houston to implant the artificial heart valve recently approved by the Food and Drug Administration, as well as a newer, smaller version that is part of a clinical trial.

21 Nov 2011

EU's FP7 programme provides €6M grant for Thyroid Hormone Replacement for Subclinical Hypo-Thyroidism Trial

Dr Patricia Kearney, Department of Epidemiology & Public Health, UCC is one of a group of researchers from European Universities who will participate in a new research project investigating current treatment practices for people who suffer from a mildly underactive thyroid gland.

21 Nov 2011

Cambridge Theranostics' liquidators set deadline for offers

Cambridge Theranostics' liquidators have set a deadline of 9 December for offers for the company's business, which includes the intellectual property of its principal product, Ateronon.

21 Nov 2011

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

21 Nov 2011